Skip to Content

Ciprofloxacin otic Pregnancy and Breastfeeding Warnings

Ciprofloxacin otic is also known as: Cetraxal, Otiprio

Medically reviewed on Feb 12, 2018

Ciprofloxacin otic Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus; caution is recommended.
-According to some authorities: Use is considered acceptable.

AU TGA pregnancy category: B3
US FDA pregnancy category:
-Otic solution: C
-Otic suspension: Not assigned.

Risk summary: Minimal risk for maternal and fetal toxicity expected when used during pregnancy.

Animal studies have not been reported. There are no controlled data in human pregnancy.

After systemic exposure to ciprofloxacin, animal studies have failed to reveal evidence of embryotoxicity or teratogenicity. Since systemic exposure to ciprofloxacin is negligible after otic administration, no harmful effects are expected during pregnancy.

AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Ciprofloxacin otic Breastfeeding Warnings

Use is considered acceptable; caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments:
-Ciprofloxacin is excreted in human milk when administered systemically.
-Maternal use of a ciprofloxacin-containing ear drop presents negligible risk for nursing infants; the effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. "Product Information. Cetraxal (ciprofloxacin otic)." WraSer Pharmaceuticals, Madison, MS.
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. "Product Information. Otiprio (ciprofloxacin otic)." Otonomy, Inc., San Diego, CA.

References for breastfeeding information

  1. "Product Information. Otiprio (ciprofloxacin otic)." Otonomy, Inc., San Diego, CA.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  3. "Product Information. Cetraxal (ciprofloxacin otic)." WraSer Pharmaceuticals, Madison, MS.
  4. Cerner Multum, Inc. "Australian Product Information." O 0
  5. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide